Kymera Therapeutics (KYMR) free cash flow

Free cash flow · fiscal 2025
-$234.34M

Kymera Therapeutics (KYMR) generated free cash flow of -$234.34M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$207.34M. Figures as of 18 Nov 2026, 12:21 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$234.34M
Highest on record
$79.03Mfiscal 2020
Lowest on record
-$234.34Mfiscal 2025
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Kymera Therapeutics free cash flow, in more detail

Across the 7 fiscal years on record (2019–2025), the highest was $79.03M in fiscal 2020 and the lowest -$234.34M in fiscal 2025.

History · 7 fiscal years

Free cash flow by fiscal year

Kymera Therapeutics free cash flow, year by year

Kymera Therapeutics (KYMR) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$234.34M—
2024-$207.34M—
2023-$137.31M—
2022-$155.92M—
2021-$130.54M 265.2% down
2020$79.03M 354.9% up
2019$17.37M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Kymera Therapeutics and comparable companies
CompanyFree cash flowFiscal year
Fresenius Medical Care FMS€1.77B2025
Kymera Therapeutics KYMR-$234.34M2025
DaVita DVA$1.31B2025
Halozyme Therapeutics HALO$356.82M2025
Universal Health Services UHS$824.55M2025
Repligen RGEN$91.69M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on KYMR

Kymera Therapeutics, figure by figure

Kymera Therapeutics (KYMR) overview: price, valuation and scorecardAll health care companies by market value

Kymera Therapeutics free cash flow: questions and answers

What is Kymera Therapeutics's free cash flow?

Kymera Therapeutics (KYMR) generated free cash flow of -$234.34M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$207.34M.

What are the highest and lowest free cash flow figures on record for Kymera Therapeutics?

Across the 7 fiscal years on record (2019–2025), the highest was $79.03M in fiscal 2020 and the lowest -$234.34M in fiscal 2025.

How is Kymera Therapeutics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Kymera Therapeutics it is on record here for 7 fiscal years, 2019 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Kymera Therapeutics (KYMR) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/KYMR/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.